State Street’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

State Street’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-235,967	Closed	-$547K	–	3871
2019 Q1	$547K	Buy	235,967 +8,149	+4%	+$22.1K	﹤0.01%	3431
2018 Q4	$529K	Sell	227,818 -4,408	-2%	-$38.9K	﹤0.01%	3435
2018 Q3	$3.44M	Buy	232,226 +13,628	+6%	+$217K	﹤0.01%	3036
2018 Q2	$3.32M	Buy	218,598 +11,572	+6%	+$196K	﹤0.01%	3049
2018 Q1	$3.89M	Buy	207,026 +160,767	+348%	+$2.81M	﹤0.01%	2914
2017 Q4	$840K	Buy	46,259 +19,952	+76%	+$422K	﹤0.01%	3382
2017 Q3	$586K	Buy	+26,307	New	+$577K	﹤0.01%	3452

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street's SNNA Position: Q2 2019 in Review

State Street sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q2 2019, closing a stake of 235,967 shares — an estimated $547K sold.

State Street first reported a position in SNNA in Q3 2017 and held it in 7 quarters. The position peaked at $3.89M in Q1 2018. 48 funds tracked by Wall St. Rank hold SNNA as of Q2 2019.

State Street reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
State Street sold 235,967 Sienna Biopharmaceuticals, Inc. shares in Q2 2019, an estimated $547K.
State Street first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 7 quarters.
State Street's Sienna Biopharmaceuticals, Inc. position peaked at $3.89M in Q1 2018.
48 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q2 2019.

Based on State Street's 13F filing for Q2 2019, filed 14 Aug 2019.